Abstract
The efficacy of high-dose intramuscular MPA therapy in controlling progressive measurable metastatic breast carcinoma was assessed in 32 women. In addition serial measurements of MPA blood levels were carried out in 20 of the patients and subjective effects of treatment were monitored in detail in 18 of the women. Overall 6 patients (19%) gained an objective response and a further 7 (22%) experienced disease stasis from 4-17 months whilst on treatment. Significant differences in serum MPA levels were seen between responders and non-responders, objective tumour shrinkage only being seen in those patients who rapidly attained, and sustained, blood levels in excess of 100 ng ml-1. Subjective assessment showed no evidence of a euphoriant effect of MPA therapy in the non-responders group.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Johnson, J., Priestman, T., Fotherby, K. et al. An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer. Br J Cancer 50, 363–366 (1984). https://doi.org/10.1038/bjc.1984.184
Issue Date:
DOI: https://doi.org/10.1038/bjc.1984.184
This article is cited by
-
Medroxyprogesterone acetate and cancer cachexia: Interleukin-6 involvement
Breast Cancer (2000)
-
Benefits of medroxyprogesterone acetate (MPA) in advanced or recurrent breast cancer with higher serum concentration
Breast Cancer (1995)
-
Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer
Cancer Chemotherapy and Pharmacology (1990)
-
Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate
Medical Oncology and Tumor Pharmacotherapy (1990)
-
Hormone treatment of meningiomas: Lack of response to medroxyprogesterone acetate (MPA)
Acta Neurochirurgica (1986)